Compare Enveric Biosciences Inc (ENVB) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs LyondellBasell Industries NV — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while LyondellBasell Industries NV trades at $60.34 (market cap $18.89B). The key difference: LyondellBasell Industries NV is far larger — about 2823.6× Enveric Biosciences Inc's market cap, and LyondellBasell Industries NV pays a 4.72% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and LyondellBasell Industries NV for 87 Days on average.
| ENVB | LYB | |
|---|---|---|
Market Cap | $6.69M | $18.89B |
Volume | 41,141 | 2,621,859 |
Sector | Health | Basic Materials |
52-Week High | $10.80 | $82.38 |
52-Week Low | $1.27 | $42.28 |
Typical Hold Time | 14 Days | 87 Days |
Enterprise Value | -$1.60M | $30.48B |
Dividend Yield | — | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
LyondellBasell (LYB) trades at $60.36, up 2.42% today, with a bearish technical signal but mixed fundamental outlook. Revenue declined to $30.15B in 2025, resulting in a net loss of $745M, though recent quarters show earnings beats. The stock is supported by a 45% analyst buy rating and a $69.38 consensus price target, but faces headwinds from cyclical chemical demand and high debt levels.
LYB offers potential upside from operational recovery and dividend yield, but risks include volatile earnings, margin pressure, and industry competition. The stock remains a speculative play on chemical sector stabilization, with investor sentiment divided between near-term challenges and long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
